Thermo Fisher plans $2.1bn note sale to help fund Phadia buy
This article was originally published in Clinica
Executive Summary
Thermo Fisher Scientific is hoping to raise $2.1bn through a senior note sale to help pay for its €2.47 ($3.5bn) acquisition of Phadia. Thermo is planning to publicly offer $1bn of its 2.25% senior notes, due 2016, at an issue price of 99.826% of the principal amount; and $1.1bn of its 3.6% senior notes, due 2021, at an issue price of 99.809% of the principal amount. The note sale is expected to close on 16 August. Thermo agreed to purchase the Swedish allergy testing firm Phadia in May, in a move that will boost its speciality diagnostics offering (www.clinica.co.uk, 19 May 2011). The joint book-runners for the offering are Barclays Capital, Merrill Lynch, Pierce, Fenner & Smith, JP Morgan Securities, Deutsche Bank Securities, RBS Securities and Goldman, Sachs & Co.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.